Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
idiotype-pulsed dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Stanford University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
Idiotype-pulsed dendritic cell vaccine is a cell-based immunotherapy where dendritic cells, either autologous or allogeneic, are pulsed ex-vivo with tumor-derived clonal immunoglobulin (the idiotype) and sometimes an immunogenic carrier protein. The idiotype is unique to each tumor and can serve as a tumor-specific antigen. After pulsing, the dendritic cells present the idiotype to the patient's immune system upon injection, stimulating tumor-specific T-cell and humoral immune responses. This approach is mainly investigated for B-cell malignancies such as follicular lymphoma and multiple myeloma, aiming to induce anti-tumor immunity and potentially achieve durable tumor regression. The vaccine can be used with or without supporting adjuvants like GM-CSF, and boosting with idiotype-carrier protein (such as Id-KLH) has been used to enhance immune responses and clinical efficacy[1][2][4].
- Other names
- idiotype-pulsed autologous dendritic cell vaccinedendritic cell-myeloma idiotype vaccineidiotype-pulsed DC vaccine
02
Targets
γδ TCR (T-cell receptor)Tumor-derived immunoglobulin idiotype peptides presented on MHC class I/II
Beyond the preview
Go deeper on idiotype-pulsed dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on idiotype-pulsed dendritic cell vaccine.